Cencora (COR) Projected to Post Quarterly Earnings on Wednesday

Cencora (NYSE:COR) is expected to issue its Q1 2026 results before the market opens on Wednesday, February 4th. Analysts expect Cencora to post earnings of $4.04 per share and revenue of $86.1184 billion for the quarter. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, February 4, 2026 at 8:30 AM ET.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The firm had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same quarter last year, the company earned $3.34 earnings per share. The company’s revenue was up 5.9% on a year-over-year basis. On average, analysts expect Cencora to post $15 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Cencora Stock Performance

NYSE COR opened at $356.15 on Wednesday. The firm has a market cap of $69.09 billion, a P/E ratio of 44.80, a price-to-earnings-growth ratio of 1.69 and a beta of 0.66. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. The company’s 50 day moving average is $348.17 and its 200-day moving average is $323.06. Cencora has a 12-month low of $237.71 and a 12-month high of $377.54.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were given a dividend of $0.60 per share. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date was Friday, November 14th. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Insider Activity at Cencora

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the sale, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the transaction, the executive vice president owned 18,796 shares of the company’s stock, valued at $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 20,316 shares of company stock valued at $7,151,265 over the last three months. 0.38% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cencora

Several hedge funds have recently added to or reduced their stakes in COR. State Street Corp increased its position in shares of Cencora by 9.3% during the 3rd quarter. State Street Corp now owns 9,190,316 shares of the company’s stock valued at $2,872,249,000 after purchasing an additional 782,911 shares during the last quarter. Boston Partners boosted its stake in Cencora by 2.0% in the third quarter. Boston Partners now owns 4,509,165 shares of the company’s stock worth $1,409,152,000 after buying an additional 89,506 shares in the last quarter. Northern Trust Corp grew its position in Cencora by 5.9% during the third quarter. Northern Trust Corp now owns 2,272,464 shares of the company’s stock valued at $710,213,000 after acquiring an additional 126,929 shares during the last quarter. Viking Global Investors LP raised its stake in shares of Cencora by 95.0% during the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after acquiring an additional 1,013,913 shares in the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Cencora by 518.9% in the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after acquiring an additional 1,672,762 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on COR. Weiss Ratings reiterated a “hold (c+)” rating on shares of Cencora in a research report on Monday, December 29th. Robert W. Baird set a $415.00 price target on Cencora in a research report on Tuesday, January 13th. Mizuho increased their price target on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Barclays began coverage on shares of Cencora in a research note on Monday, December 8th. They set an “overweight” rating and a $400.00 price objective for the company. Finally, UBS Group upped their target price on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $393.08.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.